A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.

Abstract

Twenty-eight patients who were previously treated by aggressive surgery and radiation and were diagnosed with supratentorial malignant gliomas received a combination of nimustine hydrochloride; 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cisplatin and etoposide (ACE therapy) as primary treatment. Cisplatin and etoposide were given at doses of 20 and 60 mg/m2/day for 5 days, respectively, ACNU doses 80 mg/m2/day on the first day. Treatment was repeated at 4-week intervals for up to 3 cycles. Seventeen patients (60.7%) complained of nausea. Grade 3 or 4 hematological toxicity occurred in 11 patients (39.3%), and grade 3 or 4 renal toxicity occurred in 2 patients. The percentage of patients who showed complete or partial response was 28.6% (8/28). The median time of tumor progression was 40 weeks, and the median survival time was 146 weeks. There were some long-surviving patients who may have benefited from ACE combination. This study demonstrated the effects of ACE combination in patients with supratentorial malignant gliomas.

• Authors: T Beppu, Y Yoshida, H Arai, T Wada, M Suzuki, A Ogawa, S Hakozaki, N Kubo
• Journal: Journal of neuro-oncology (J Neurooncol) Vol. 49 Issue 3 Pg. 213-8 (Sep 2000) ISSN: 0167-594X [Print] United States
• PMID: 11212900 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Phytogenic
• Nimustine
• Etoposide
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage)
• Antineoplastic Agents, Phytogenic (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cerebellar Neoplasms (drug therapy)
• Cisplatin (administration & dosage)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Etoposide (administration & dosage)
• Female
• Glioma (drug therapy)
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Nimustine (administration & dosage)
• Survival Analysis
• Treatment Outcome